Curocell Inc. (KOSDAQ:372320)
40,150
-1,450 (-3.49%)
Last updated: Nov 14, 2025, 9:00 AM KST
Curocell Company Description
Curocell Inc. develops CAR-T cell therapy for the treatment of cancer.
It focuses on the development of CD19 CAR-T for the treatment of lymphoma; and BCMA CAR-T for the treatment of multiple myeloma.
The company was incorporated in 2016 and is based in Daejeon, South Korea.
Curocell Inc.
| Country | South Korea |
| Founded | 2016 |
| Industry | Biological Products, Except Diagnostic Substances |
Contact Details
Address: 48, Yuseong-daero 1184beon-gil Daejeon, 34109 South Korea | |
| Phone | 82 4 2863 3698 |
| Website | curocellbtx.com |
Stock Details
| Ticker Symbol | 372320 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |